ArticleCureus2026
Refractory Autoimmune Hemophagocytic Lymphohistiocytosis in Adults: Multi-therapy Failure and the Limits of Salvage Transplantation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article presents a case of refractory autoimmune-associated hemophagocytic lymphohistiocytosis (HLH) complicating systemic lupus erythematosus in a young adult. It highlights the diagnostic difficulty created by overlapping features of infection, autoimmune flare, and cytokine-driven hyperinflammation, and details disease progression despite corticosteroids, etoposide, multiple biologic agents, and consideration of hematopoietic stem cell transplantation (HSCT). The discussion broadens to review the epidemiology of autoimmune-triggered HLH in adults, reported response rates to cytokine-directed therapies, the limited role and toxicity of salvage cytotoxic regimens, and contemporary HSCT outcomes, which demonstrate variable survival but remain the only potentially curative strategy in selected patients. Clinicians managing patients with severe or treatment-resistant autoimmune disease should maintain a low threshold for suspecting HLH when cytopenias, hyperferritinemia, or unexplained organ dysfunction emerge. Early calculation of the HScore and prompt initiation of therapy are critical to reducing diagnostic delay. While definitive management requires control of the underlying immune dysregulation, treatment of active hyperinflammation should not be postponed during ongoing evaluation and multidisciplinary planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.